Goodwill

9 Months Ended

Mar. 31, 2020

GOODWILL

The following table summarizes the changes between June 30, 2019 and March 31, 2020 in the carrying amount of goodwill in total and by reporting segment:


(Dollars in millions)	Softgel & Oral Technologies		Biologics		Oral & Specialty Delivery		Clinical Supply Services		Total
Balance at June 30, 2019	$	409.2	$	1,320.0	$	340.3	$	151.4	$	2,220.9
Additions	—		260.6		—		—		260.6
Reallocation	108.1		(124.3)		16.2		—		—
Other	(1.4)		(6.8)		1.1		—		(7.1)

Foreign currency translation adjustments	(13.0)		(1.3)		(6.0)		(4.8)		(25.1)
Balance at March 31, 2020	$	502.9	$	1,448.2	$	351.6	$	146.6	$	2,449.3

The addition to goodwill in the Biologics reporting segment relates to the Novavax and MaSTherCell transactions. See Note 3, Business Combinations. The reallocation of goodwill relates to the adjustments to the Company’s reporting segments, as a result of which certain assets moved from the Biologics reporting segment to the Oral and Specialty Delivery reporting segment, and other assets moved from the Oral and Specialty Delivery reporting segment to the Softgel and Oral Technologies reporting segment. The Company recorded no impairment charge to goodwill in the current period.